These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16918897)

  • 1. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
    Mehrotra DV; Li X; Gilbert PB
    Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chop-lump tests for vaccine trials.
    Follmann D; Fay MP; Proschan M
    Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extended general location model for causal inferences from data subject to noncompliance and missing values.
    Peng Y; Little RJ; Raghunathan TE
    Biometrics; 2004 Sep; 60(3):598-607. PubMed ID: 15339281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
    Baker SG; Fitzmaurice GM; Freedman LS; Kramer BS
    Biostatistics; 2006 Jan; 7(1):29-40. PubMed ID: 15923407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity.
    Shepherd BE; Gilbert PB; Dupont CT
    Biometrics; 2011 Sep; 67(3):1100-10. PubMed ID: 21114663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principal stratification with predictors of compliance for randomized trials with 2 active treatments.
    Roy J; Hogan JW; Marcus BH
    Biostatistics; 2008 Apr; 9(2):277-89. PubMed ID: 17681993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SAS macro for constrained randomization of group-randomized designs.
    Chaudhary MA; Moulton LH
    Comput Methods Programs Biomed; 2006 Sep; 83(3):205-10. PubMed ID: 16870302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T; Gilbert PB; Self SG
    J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217.
    Messer K; Vaida F; Hogan C
    Contemp Clin Trials; 2006 Dec; 27(6):506-17. PubMed ID: 16962381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
    O'Malley AJ; Normand SL
    Biometrics; 2005 Jun; 61(2):325-34. PubMed ID: 16011678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization.
    Shepherd BE; Gilbert PB; Lumley T
    J Am Stat Assoc; 2007 Jun; 102(478):573-82. PubMed ID: 19122791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring HIV vaccine efficacy.
    Hernández-Suárez CM
    Stat Med; 2005 Apr; 24(7):983-92. PubMed ID: 15568204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.